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Abstract
Background: There are very few studies about general quality of life parameters, standards for the description of
health status and comparison with general population data on patients with Hereditary hemorrhagic telangiectasia
(HHT), a rare disease in which epistaxis is a cardinal symptom.
Purpose: To assess the quality of life in a population of Spanish patients with HHT and compare it with the general
population.
Design and methods: Between January 1st 2005 and December 31st 2013, 187 adult patients diagnosed with HHT
who were admitted to the HHT Unit of the Hospital Sierrallana, completed on their first visit, the EuroQol 5D-3L
(five dimensions and three levels) quality of life descriptive test and the visual analog scale (VAS). The numerical
social index value was also determined and the subjective effect of the nasal epistaxis on their quality of life was
estimated classified as mild, moderate or severe.
Results: Patients with HHT had greater problems than the general population in the five dimensions of the
EuroQol 5D-3L, particularly considering pain/discomfort and anxiety/depression. In the VAS and the social index
value, patients with HHT also scored lower than the general population, particularly older patients, males, and
patients with HHT2. They also had values similar to those of populations with chronic illnesses. The subjective
perception of the severity of epistaxis correlated strongly with the VAS and social index values.
Conclusions: The quality of life of patients with HHT, estimated using the EuroQol 5D-3L scale, is affected across all
dimensions. The scores are similar to those seen in cases of other chronic diseases. Older patients, males and the
carriers of the ACVRL1 mutation generally have worse scores on these scales. The VAS and the social index value are
index that correlate well with the severity of the clinical symptoms associated mainly with epistaxis.
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Background
Hereditary hemorrhagic telangiectasia (HHT) or Osler-
Weber-Rendu syndrome (ICD 9 448.0 [1] / ICD 10
178.0 [2] / ORPHA774) is an autosomal dominant gen-
etic disease. It is characterized by the appearance of
anomalous vascular structures: telangiectasias (small in
size) or arteriovenous malformations (AVM). The latter
are complex and larger in size. These vascular anomalies
may appear in any organ and are responsible for the
morbidity and mortality associated with this disease. The
symptoms are variable in their penetrance, and are af-
fected by a number of factors, including but not limited
to age, sex and genotype. Epistaxis is the most frequent
clinical manifestation: up to 96% of patients may exhibit
nasal bleeding and it is generally the first symptom to
appear [3]. HHT is classified as a rare or minority
disease since its average prevalence is estimated at
1:5000–1:8000 [4], still remaining under-diagnosed [5], and
associated with a significant morbidity and mortality [6]. At
this moment there is no definitive cure for this disease.
Various genes involved in the development of the dis-
ease have been identified (Table 1).
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The diagnosis of the illness is based on the Curaçao’s
diagnostic criteria [7, 8]. These are: epistaxis, telangiecta-
sias, dominant familial aggregation and effects on in-
ternal organs. At least three must observed in order to
confirm a diagnosis. Otherwise, a diagnosis can be per-
formed by identifying, via molecular study, a suspected
causative mutation.
There are few studies that provide reference population
data, standards for the description of health status, or gen-
eral quality of life parameters in HHT patients. Further-
more, the majority of publications apply the SF-36 scale
(original or abbreviated). At the present time, no quality
of life scale has been validated specifically for HHT but a
questionare of specific symptoms linked with HHT per-
formed on a sample of German patients within a profile of
quality of life of chronically ill patients survey [9]. The
HHT Unit at the Hospital Sierrallana has been listed by
the International HHT Foundation (www.hht.org) as
international excellence center and it has functioned as a
reference unit for this pathology in Spain since 2002. With
authorization from theEuroQol Group (http://www.euro-
qol.org/), the Unit has applied the Euroquol-5D-3L scale
since 2005 [10]. This scale is a generic, standardized tool
that is being developed internationally since 1990.
Euroquol-5D-3L is used to describe and assess the self-
perceived quality of life in the area of health.
Therefore, the aim of our study was to investigate the
quality of life in a population of Spanish patients with
HHT and compare it with the general population.
Population and methods
The study was performed at the Hospital Sierrallana
(Torrelavega, Cantabria, Spain). The HHT Unit of this
hospital serves as a reference unit for the population of
Cantabria and Spain. Accreditation is pending, according to
legislation governing the appointment of reference centers
and units (Royal Decree 1302/2006). According to census
figures published on the 1st of January 2014 by the Spanish
National Statistics Institute, INE), Cantabria had 587,686
inhabitants and the population of Spain was 46,507,760.
This was a descriptive, cross-sectional, observational
study and included adult patients treated at the HHT
Unit at the Hospital Sierrallana (General Medicine)
diagnosed with HHT (clinical and/or genetic) between
2005 and 2013, who were asked to complete the Euro-
Qol 5D-3L quality of life scale upon their first admission
or consultation as well as provide a subjective valuation
of the impact that epistaxis had on their health status
(these last valuation was categorized as mild, moderate
or severe based on self perceived impairment for normal
life compared with an ideal status).
The EuroQol 5D consists of two parts. The first part is
a descriptive system of health status. The system allo-
cates a numerical 5-digit code. Each digit oscillates from
1 to 3 (no problems, some problems, and significant
problems, respectively). The following dimensions were
rated: mobility, self-care, usual activities, pain/discomfort
and anxiety/depression. The three level version is used
in the HHT Unit as this was the only version available
when the system was first introduced. A five level ver-
sion has also been available since 2009, however. From
this descriptive system a social index value is obtained
using a formula calculated according to the individual
studies for the population of each country or region in
which the best health status would be assigned a score
of “1”, for full health. The worst health status would be
death, which would be assigned a score of “0” [10].
The second part of the EuroQol 5D is a visual analog
scale (VAS or EuroQol thermometer) that automatically
assigns the patient a score between 0 and 100 (where 0
is the worst health status imaginable and 100 the best)
in a vertical bar indicating a score for their perceived
quality of life.
The following variables were analyzed:
 EuroQol code (descriptive, numerical qualitative
variable)
 EuroQol social index value (continuous, quantitative
variable)
 EuroQol VAS (continuous, quantitative variable)
 Subjective perception of general health status
regarding impact of epistaxis (descriptive,
categorical, qualitative variable) based on self
perceived impairment for normal life compared with
an ideal status).
The EuroQol 5D profile was dichotomized into ‘no
problems’ and ‘moderate/extreme problems’.
To compare quality of life in HHT patients with gen-
eral population we used data of the Spanish national
health survey (ENSE) performed in 2011/2012 based on
a sample of 26,502 people and data from the Navarre
general population health survey of 1995 (n = 3000) [11].
Aditionally data from the Catalonian health survey
(ESCA) of 1995 (n = 12,445 people) [12] was used both
to compare HHT patients with general population and
with patients with chronic diseases.
Table 1 Genes involved in HHT
HHT OMIM Chromosome Gene Protein
HHT 1 #187300 9 ENG endoglin
HHT 2 #600376 12 ACVRL1 ALK1
HTJP #175050 18 MADH4 Smad 4
HHT 3? 5
HHT 4? 7
SMCMA 14 BMP9 (GDF2) BMP9
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Statistical analysis
Data were summarized as mean and standard deviation
(SD) and median with interquartile range (IQR: p25-p75)
for continuous variables, and frequency (%) for categorical
variables. Statistical analysis was performed using two-
tailed χ2 and Fisher’s exact test when necessary, one-way
ANOVA test or Mann–Whitney U test or Kruskal-Wallis
test, as appropriate in each case. For m x n contingency
tables in which observed frequencies occupy m rows and
n columns, a Fisher’s exact test was estimated using the
Monte Carlo method. A two-tailed p < 0.05 was consid-
ered statistically significant. Statistical data clean-up and
analysis were performed with the SPSS 22.0 program
(IBM Inc. Chicago IL, USA).
Results
Between 1 January 2005 and 31 December 2013, a total
of 187 adult patients with HHT (96 women and 91 men)
completed the descriptive scale and the visual analog
scale (EQ-VAS) of the EuroQol 5D-3L tool. Distribution
regarding age and sex is shown in Fig. 1. The average
age of the patients was 48.8 years (SD: 14.8). Among the
women, the average was 47.7 years (SD: 14.2). Among
the men, the average age was 49.9 (SD: 15.4) (p = 0.29).
Sixty six patients (35.3% of the total) were cases of
HHT1; 57.8%, or 108 patients, were cases of HHT2. On
12 occasions, no mutations were identified (6.4%). A sin-
gle patient presented a Smad 4 mutation (0.5%).
Descriptive analysis considering health status dimensions
The health status results sorted according to the propor-
tion of patients in each level of the five dimensions ana-
lyzed and by age subgroups showed that dimensions of
pain/discomfort and anxiety/depression stood out the
most among patients with HHT (47.6 and 43.9% of pa-
tients with problems, respectively). Meanwhile, self-care
was the least affected dimension (14 patients, 7.5%).
Patients over 60 years had the worst overall scores. The
middle aged (aged 40 to 59) presented the biggest changes
in their daily activities and in the level of their pain/dis-
comfort. A worsening in the values considering all dimen-
sions was observed when ageing of patients; this was
significant in mobility (p < 0.0001), and nearly significant
regarding self-care and anxiety/depresión (p = 0.06).
In terms of the presence of problems (levels 2 and 3)
vs. absence of problems (level 1), in each dimension, we
found that there was greater proportion of differences
with age in the dimensions of anxiety/depression and
pain/discomfort (Table 2).
Elderly patients aged between 60–69 years exhibited
the greatest deterioration in almost all dimensions. The
exception was in daily activities, where the 50–59 and
60–69 age groups had the lowest score. In the dimen-
sion of self-care, the most affected population was also
the 60–69 age group.
Comparing the analysis of the HHT population with
the 2011/2012 Spanish national health survey, HHT pa-
tients reported significantly more severe problems in all
the descriptive system dimensions except in the self care
dimension (Fig. 2).
In adition, the descriptive health status parameters of
studies performed in Spain of the both general population
and patients with chronic pathologies were compared
(Table 3). Here, the EQ-5D-3 L was used in both the Cata-
lonian health survey of 1995 and the Navarre general
population health survey of 1995. In this case the differ-
ences between HHT patients and general population were
statistically significant in all dimensions of EQ-5D.
Comparing populations of individuals with chronic dis-
eases with our sample of HHT patients, percentages
showed similar results but mobility was more affected in
the case of chronic conditions compared with HHT (p =
0.023) with a higher percentage of cases in level 2, while in
the rest of dimensions the differences were not significant.
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60-69 15 17
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Fig. 1 Distribution of HHT patients sorted by age and sex
Zarrabeitia et al. Health and Quality of Life Outcomes _#####################_ Page 3 of 9
Analysis of the visual analogue scale
The values of the visual analogue scale ranged from 0 to
100, with 0 being the worst subjective perception of health
status, and 100 being the best. The mean VAS score was
73.7 (SD 19.0), and the median value was 80 (IQR 30).
The scores were similar in men and women (median VAS
score of 80 in both groups; p = 0.57). However, the VAS
score worsened significantly with age generally (median
score range from 90 in youngest aged group to 70 in old-
est group; p = 0.001) and in the male group, in particular
(p = 0.03), but not in female (p = 0.16) (Fig. 3). The scores
were lower in patients with HHT 2 and in patients with-
out an identified mutation (NO ID), although this differ-
ence was not statistically significant (Table 4).
In comparison to historical data, patients with HHT
had higher mean VAS scores in perceived health status
(73.7) compared with those obtained in the ESCA (71.3)
and Navarre general population (71.6). Also reports
about patients with chronic diseases showed lower
means scores (63.9). However when comparing by age
group with the EQ-VAS values from the 2011/2012
Spanish national health survey, patients with HHT pre-
sented lower values in all cases but in the oldest (>70)
(probably biased because of the lower number of pa-
tients). This effect was significative in the groups aged
between 35 and 54. The average values in the case of
HHT were also lower than those of the general popula-
tion (73.7 vs. 77.5).
Social index value analysis
Social index values laid on in Table 5, showed a mean
value of 0.77 (SD 0.19), with a median value of 0.79
(IQR 0.11). Distribution of results regarding age are
shown in Fig. 3 with values ranging from 0.92 (youngest)
Table 2 Percentage of patients with problems (yes) vs. absence of problems (no) in each of the EQ-5D dimension according to
general characteristics
Mobility Self-care Daily Activities Pain/ Discomfort Anxiety/Depression
No Yes No Yes No Yes No Yes No Yes
Total (n)
%
141
75.4
46
24.6
173
92.5
14
7.5
141
75.4
46
24.6
98
52.4
89
47.6
105
56.1
82
43.9
Age (yr) (%)
18–29 100 0 100 0 84.6 15.4 76.1 23.9 73.1 26.9
30–39 92.3 7.7 75.1 24.9 47.8 52.2 58.2 41.8 62.9 37.1
40–49 57.5 42.6 57.9 42.1 62.1 37.9 47.7 52.3 52.2 47.8
50–59 47.3 52.7 53.2 46.8 44.5 55.5 48.8 51.2 45.0 55.0
60–69 24.5 75.5 22.5 77.5 35.2 64.8 38.4 61.6 34.8 65.2
>70 20.7 79.3 58.0 42.0 53.2 46.8 36.4 63.6 38.4 61.6
P-value* <0.0001 0.06 0.14 0.11 0.06
*Two-tailed Chi-squared test or Fisher exact test as corresponding
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Fig. 2 Comparison of percentages that report problems in each of the dimensions between HHT and Spanish health survey
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to 0.65 (elderly). The differences in values were statisti-
cally significant in the case of the overall population (p
< 0.001) and when stratified by sex (range from 0.92 to
0.61 from younger to older male patients, p < 0.001,
range from 0.61 to 0.63 in women, p = 0.017). On the
other hand, no significant differences were observed
with respect to sex (median score of 0.76 in male and
0.79 in females; p = 0.86). With respect to genetics, pa-
tients with HHT type 1 or HHT type 2 had no signifi-
cant higher scores than those without a mutation
identified (p = 0.18).
The comparison between the values for general popu-
lations and for people with chronic illnesses with the
values for patients with HHT is presented in Table 6.
The HHT had a lower score in comparison with the
general population and one study of general patients
(median score 1.00 vs. 0.79). However, this result is simi-
lar in the case series of patients with chronic pathologies
(median score 0.78).
Analysis of the subjective severity of the impact of
epistaxis on quality of life
The impact of epistaxis on quality of life was classified
either as mild, moderate or severe (Table 7). This did
not vary according to sex (p = 0.66).
All patients of both sexes in younger ages (18–29 years)
referred to the impact as mild. Meanwhile, the percentage
of patients who reported a moderate and severe impact in-
creased significantly with age in both (p < 0.001). There
Table 3 Comparison of the population of HHT with Spanish studies of the general population and patients with chronic diseases
(%)
Eq-5d Levela General Population Patients (general) HHT Patients %
(N = 187)Cataluña10 %
(N = 12245)
Navarra9 %
(N = 3000)
Chronical10 %
(N = 120)
Mobility 1 89.1 85.3 63.3 75.4
2 10.7 14.7 36.7 24.6
3 0.2 0 0 0
Self care 1 98.0 96.6 91.7 92.0
2 1.8 3,4 8.3 8.0
3 0.2 0 0 0
Daily Activities 1 93.6 89.0 85.8 75.4
2 5.8 9.7 12.5 20.3
3 0.6 1.3 1.7 4.3
Pain/Discomfort 1 74.2 70.6 42.5 52.4
2 21.1 23.7 49.2 44.4
3 4.7 5.7 8.3 3.2
Anxiety/Depression 1 86.3 82.2 62.5 56.1
2 11.4 14.1 30.8 39.6
3 2.3 3.7 6.7 4.3
a1 no problems, 2 some problems, and 3 significant problems
Fig. 3 Distribution of VAS score and social index regarding age
Zarrabeitia et al. Health and Quality of Life Outcomes _#####################_ Page 5 of 9
was no statistically significant difference in the impact of
epistaxis with respect to genetics (p = 0.26).
On average, patients reporting a moderate to severe
impact were older, with a mean age of 57.1 (SD 11.7)
years in patients with severe impact and 52.5 (SD 12.4)
years in them with moderate impact; mean age of
patients with mild impact of epistaxis was 43.6 (SD 15.1)
years, being this differences statistically significant (p <
0.0001). This effect held for women and men separately:
(male: mild, moderate, severe respectively: 43.7 (16.1),
56.9 (11.7), 56.8 (11.0), p < 0.001 and female: 43.5 (14.1),
49.0 (12.0), 57.6 (14.2), p = 0.001).
The relationship between parameters of quality of life
and the subjective severity of the impact of epistaxis
In the case of both quality of life scales, EQ-VAS and the
social index value of the EuroQol 5D-3 L, a statistically
significant association was observed between the per-
ceived severity of nasal epistaxis (nosebleeds) in HHT pa-
tients, and the repercussion of the epistaxis on their
quality of life. The mean VAS score was 80.1, 74.5 and
55.5 for patients referred mild, moderate and severe im-
pact of epistaxis respectively (p < 0.0001). Similarly, the
mean social index values was 0.82, 0.78, 0.61 respectively
Table 4 VAS values sorted by demographic and genetic
characteristics
Variable EQ VAS
n Mean (SD) Median (p25-p75) P-value*
Sex
Male 91 74.1 (19.8) 80 (65–85)
Female 96 73.2 (18.1) 80 (60–90) 0.57
Age (yr)
18–29 18 87.5 (10.9) 90 (80–96.25)
30–39 38 79.7 (17.2) 85 (68.75-95)
40–49 36 70.8 (19.3) 77.5 (55–83.75)
50–59 45 69.3 (19.7) 75 (55–82.5)
60–69 32 68.1 (18.4) 72.5 (52.5-80) 0.001
> 70 18 73.6 (19.3) 70 (58.75-92.5)
HHT Type
HHT1 66 75.7 (17.3) 80 (65–90)
HHT2 108 73.7 (19.6) 80 (61.25-90)
Smad4 1 20 20
No ID 12 67.1 (15.3) 65 (51.25-80) 0.13
*Two-tailed independent samples Mann–Whitney U test or Kruskal-Wallis test
as corresponding
Table 5 Social index values sorted by demographic and genetic
characteristics
Variable Social Index
n Mean (SD) Median (p25-p75) P-value*
Sex
Male 91 0.77 (0.20) 0.76 (0.69-1.00)
Female 96 0.76 (0.19) 0.79 (0.69-0.80) 0.86
Age (yr)
18–29 18 0.92 (0.12) 1.00 (0.80-1.00)
30–39 38 0.83 (0.16) 0.79 (0.74-1.00)
40–49 36 0.79 (0.20) 0.79 (0.71-1.00)
50–59 45 0.74 (0.19) 0.74 (0.67-0.80)
60–69 32 0.65 (0.20) 0.70 (0.59-0.79) <0.001
> 70 18 0.70 (0.17) 0.72 (0.66-0.80)
HHT Type
HHT1 66 0.78 (0.17) 0.79 (0.70-1.00)
HHT2 108 0.76 (0.21) 0.79 (0.68-1.00)
Smad4 1 0.11 0.11
No ID 12 0.73 (0.12) 0.74 (0.69-0.79) 0.18
*Two-tailed independent samples Mann–Whitney U test or Kruskal-Wallis test
as corresponding
Table 6 Social index values of the HHT population in
comparison to the studies in general population and the
population of patients with chronic diseases in Spain
Social Index
n Mean Median Minimum Maximum
General population
Catalonia10 12245 0.89 1.00 −0.08 1.00
Navarre9 300 0.87 1.00 0.12 1.00
Cronical patients10 120 0.75 0.78 0.17 1.00
HHT patients 187 0.77 0.79 0.11 1.00
Table 7 Subjective perception of severity of epistaxis impact
sorted by demographic and genetic characteristics
Epistaxis subjective impact
n Mild (%) Moderate (%) Severe (%) P-value*
Sex
Male 91 52.7 25.3 22.0
Female 96 52.1 30.2 17.7 0.66
Age (yr)
18–29 18 100.0 0.0 0.0
30–39 38 60.5 31.6 7.9
40–49 36 61.1 22.2 16.7
50–59 45 37.8 35.6 26.7
60–69 32 37.5 34.4 28.1
> 70 18 33.3 27.8 38.9 0.001
HHT Type
HHT-1 66 54.5 28.8 16.7
HHT-2 108 49.1 28.7 22.2
Smad4 1 0.0 0.0 100.0
No ID 12 75.0 16.7 8.3 0.26
*Two-tailed Chi-squared test or Fisher exact test as corresponding
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(p < 0.0001). This effect held overall, and for women and
men separately (men: 0.84, 0.76, 0.62; p < 0.0001); women:
0.81, 0.80, 0.59 (p < 0.0001).
Discussion
The quality of life of patients is affected by HHT. This is
due largely to the nasal epistaxis they suffer, which is
generally the most prevalent symptom among this popu-
lation. Other clinical features are bleeding from the
gastrointestinal system and symptoms due to develop-
ment of pulmonary, hepatic and brain arteriovenous
malformations. Some studies on pharmacological or sur-
gical interventions in patients with HHT apply quality of
life scales (SF-36) as a variable in evaluating responses.
Some examples are the studies of the effects of bevacizu-
mab, N-acetylcisteine, and silicone nasal swabs on epi-
staxis [13–15]. However, few studies provide reference
population data, health status standards, and general
quality of life parameters. Furthermore, in the majority
of publications, either the original or abbreviated SF-36
scale is applied. Examples are a Norwegian case series
with 66 patients [16], an Italian case series with 50 pa-
tients [17], and a German study of 77 cases [18]. All
these three studies had lower SF-36 scores excepting
values in the category of pain, in two of the three stud-
ies. Also, in the third study, the worst score was reported
in patients with gastrointestinal and hepatic symptoms.
A German study performed on a population with HHT
using the questionnaire of “Profile of quality of life of
chronically ill patients” with an specific area for symp-
toms related with the condition, showed the epistaxis as
the most disturbing symptom while HHT patients pre-
sented worse results in five of the six scales listed com-
pared with patients with chronic pathologies as
cardiomyopathy or rheumatic disease [9].
Despite attempts to create specific severity scales for
patients with HHT, there are still no tools that are
widely accepted. Only the HHT-Epistaxis Severity Score
(HHT-ESS) [19] seems to be a promising indicator. This
is due to its strong correlation with the SF-36 method.
Even so, it is only valid as a measure of post-
intervention monitoring of efficacy [20]. In 2011, a spe-
cific 13 item scale for estimating quality of life in HHT
patients was proposed as complement to SF-36. How-
ever, this system is not yet validated, and is not widely
employed [21]. Since 2005, the EQ-5D-3L questionnaire
has been used for adult patients being treated in the
HHT Unit [22]. EQ-5D-3L is a generic and standardized
instrument created in 1990. It has been adopted because
of its simplicity and its potential applications for post-
intervention clinical efficacy studies as well as for esti-
mations of quality-adjusted years of life. In 2009, the
EuroQol Group launched a new version of the tool (EQ-
5D-5L). However, in the present study, we used the
original version and this was in order to be able to in-
clude the data from patients treated between 2005 and
2009. In the descriptive part of the present study and
considering the five dimensions of the EuroQol, it was
common for older patients to have a higher percentage
of problems across the board in case series from the
general population. Nevertheless, it is significant that the
total HHT population had a higher than average level of
problems in all dimensions, in comparison to data from
the Spanish national health survey from 2011–2012 [23].
This was true all cathegories but self care. In HHT pa-
tients, anxiety/depression appears proportionally higher
than in the general population, even though it was
exceeded by the perception of pain/discomfort. High
rates of clinical anxiety and depression in HHT patients
have been reported, especially in women [24]. Therefore,
there is a need for an appropriate system for prevention
and treatment to be developed in this area.
Since the EuroQol 5D tool was introduced in Spain,
various studies of the general population have been car-
ried out with this tool. For example, EuroQol 5D was
used in the health surveys of Catalonia and Navarre in
1995. It has also been used to study subgroups of pa-
tients with chronic and critical diseases. If we compare
the percentage of problems reported by the HHT popu-
lation analyzed with the available data from these popu-
lations, the data, as expected, fits neatly with that of the
case series of patients with chronic pathologies. This re-
sult is consistent with the chronic nature and the pene-
trance of HHT symptoms. In the case of EQ-VAS, there
are no significant differences according to sex or genet-
ics but the oldest group showed a significant lower
score. Moreover there are differences with the general
population: the mean score is 3,86% lower in HHT data
than in ENSE data. However, this score is higher than
the one reported for the general population and for pa-
tients with chronic pathologies in previous studies.
These data indicate that there may have been a bias in
the data as a result of how patients are selected for treat-
ment in the HHT Unit. For example, they may have
been selected according to their ability to travel. On the
other hand, the social index values in the HHT popula-
tion were comparable with values from chronic patients.
Thus, the social index value seems to be a more reliable
tool for carrying out comparative studies. It is not pos-
sible to compare with the data from ENSE 2013. This is
because the social index value is calculated using for-
mula from the EuroQol 5D-5L. According to the social
index value, age is associated with poor scores. This is
particularly true in men, which is unusual, because, ac-
cording to the ENSE, men tend to rate their health
higher than women.
In order to acquire an additional indicator of the per-
ception of quality of life perception that was specifically
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related to epistaxis, patients were asked to classify the
impact of nosebleeds as mild, moderate, or severe. Once
again, age was a primary factor. However the result was
slightly more prominent in men. During their fertile
years, women could have a hormonal ‘protective’ mech-
anism against epistaxis due to estrogen effects on nasal
mucose wall thickening [25], coagulation improvement
[26] and expression of endoglin in endothelial cells [27]
while in men, the deleterious effects seem to be continu-
ous and normally increase over time.
Finally, we examined the reliability of EuroQol 5D in
estimating the impact on the quality of life of HHT pa-
tients of their most debilitating symptom. A significant
correlation was found between the perceived severity of
epistaxis (mild/moderate/severe), the EQ-VAS, and the
social index value. This held true for the overall popula-
tion and for the sexes separately. Therefore, they are
valid methods for estimating the health status of this
population regarding its main symptom. The genetics
only influenced the quality of life results for HHT2 pa-
tients in the case of the lowest social index values. In
support of a probable genetic influence, a prior study of
a small number of patients postulated that one could
distinguish between HHT2 and HHT1 patients. In the
case of HHT2 patients, there was a bigger effect on the
physical dimensions of SF-36, while with HHT1 patients,
there was a greater effect in the area of mental health
[28]. Recently, the quality of life of 127 Argentinian pa-
tients was evaluated using EuroQol 5D-3L. The average
EQ-VAS score was 69 (ICR: 20.3). This was less than the
EQ-VAS value of the Spanish population. This is likely
because in this study, a higher percentage of patients re-
ported having epitaxis (33.3% vs. 19.2%) [29].
Conclusions
Pain/discomfort and anxiety/depression were the quality
of life dimensions most altered in HHT patients with in
Spain. There was an increase, with age, in the frequency
of problems. Compared to the general population, pa-
tients with HHT had higher percentages of problems in
the five dimensions analyzed. This result was similar in
case series of patients with chronic diseases.
EQ-VAS quantitative values assigned by HHT patients
were generally lower than those assigned by members of
the general population. There were no significant differ-
ences between sexes. The score decreased according to
age in the group as a whole. This result was most signifi-
cant with men.
HHT patients had lower social index values than the
general population. These values were comparable in
case series of patients with chronic diseases. The score
worsened significantly with age (in the group as a whole
and in men).
Both male and female HHT patients who were older
perceived the impact of nasal epistaxis on their quality
of life as more severe.
There was a statistically significant association be-
tween EQ-VAS values and social index values of the per-
ception of the severity of epistaxis. The EuroQol 5D-3L
seems to be a valid tool for estimating the impact of epi-
staxis on the quality of life.
Assessment of bias
Probable selection bias:
 Although the population studied included patients
from practically the whole of the national territory,
the majority originated from Cantabria and
bordering communities.
 Patients from regions outside Cantabria who are
admitted to the HHT Unit have a health status that
allows them to travel. Therefore, there may have
been a certain bias towards more moderate effects.
 Demographic characteristics of the groups of
general populations and patients with chronic
diseases analysed and compared with HHT
population may vary specially in those studies with
lower number of patients.
Probable information bias:
 The EuroQol 5D-3 L scale used to evaluate the
health status in patients, has a ‘ceiling effect’ in its
descriptive section used to distinguish between
health statuses in relatively healthy populations. Also
it cannot be applied in pediatric age groups.
Despite these possible limitations, the sample size and
the overall characteristics of the sample appear to have
been sufficiently representative. There was no noticeable
observer bias, since it was always the same person who
carried out the survey and documented the results.
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